SLE patients with anti-RNP and anti-Sm antibodies were more prevalent in the IFN3α high-score group than in the low-score group in SLE (calculated with IFI44, IFIT1, and PRKR). This evidence concerns the gene EIF2AK2 and systemic lupus erythematosus.